Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Taurine up-regulated gene 1 (TUG1) is a well-studied long non-coding RNA (lncRNA) originally identified as being upregulated by taurine treatment in developing retinal cells. It does not encode a protein. TUG1 serves as a molecular regulator in a wide variety of biological processes, particularly in cancers, where it is frequently abnormally expressed. It facilitates tumor progression by modulating cell proliferation, invasion, migration, apoptosis, cell cycle, and drug resistance. Mechanistically, TUG1 functions through a combination of acting as a sponge for tumor-suppressive microRNAs (such as miR-143-5p and miR-498), recruiting RNA-binding proteins for chromatin remodeling, and influencing gene transcription and genome stability through R-loop regulation. TUG1’s expression levels correlate with clinical prognosis and therapeutic response in multiple cancer types and are thus viewed as potential biomarkers and therapeutic targets. However, context-specific effects—including both oncogenic and tumor-suppressive properties—have been reported, and direct therapeutic targeting is primarily investigational, focusing on nucleic acid–based strategies rather than small molecules.
Acts as a competing endogenous RNA (ceRNA), sponging specific microRNAs (e.g., miR-143-5p, miR-498) Interacts with and recruits RNA-binding proteins (e.g., heterogeneous nuclear ribonucleoproteins, poly(ADP-ribose) polymerase 1) Epigenetic regulation of gene expression, including histone modification complexes Influences angiogenesis and cell signaling in cancer progression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Taurine up-regulated gene 1 (long non-coding RNA) (TUG1).